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We previously reported that the human Na/nucleo-
side transporter pyrimidine-preferring 1 (hCNT1) is
electrogenic and transports gemcitabine and 5-deoxy-
5-fluorouridine, a precursor of the active drug 5-fluoro-
uracil. Nevertheless, a complete electrophysiological
characterization of the basic properties of hCNT1-medi-
ated translocation has not been performed yet, and the
exact role of adenosine in hCNT1 function has not been
addressed either. In the present work we have used the
two-electrode voltage clamp technique to investigate
hCNT1 transport mechanism and study the kinetic
properties of adenosine as an inhibitor of hCNT1. We
show that hCNT1 exhibits presteady-state currents that
disappear upon the addition of adenosine or uridine.
Adenosine, a purine nucleoside described as a substrate
of the pyrimidine-preferring transporters, is not a sub-
strate of hCNT1 but a high affinity blocker able to in-
hibit uridine-induced inward currents, the Na-leak
currents, and the presteady-state currents, with a Ki of
6.5 M. The kinetic parameters for uridine, gemcitabine,
and 5-deoxy-5-fluorouridine were studied as a function
of membrane potential; at 50 mV, K0.5 was 37, 18, and
245 M, respectively, and remained voltage-independ-
ent. Imax for gemcitabine was voltage-independent and
accounts for 40% that for uridine at 50 mV. Maximal
current for 5-DFUR was voltage-dependent and was
150% that for uridine at all membrane potentials.
K0.5
Na for Na was voltage-independent at hyperpolar-
ized membrane potentials (1.2 mM at 50 mV), whereas
Imax
Na was voltage-dependent, increasing 2-fold from
50 to 150 mV. Direct measurements of 3H-nucleoside
or 22Na fluxes with the charge-associated revealed a
ratio of two positive inward charges per nucleoside and
one Na per positive inward charge, suggesting a stoi-
chiometry of two Na/nucleoside.
Nucleoside uptake into cells occurs through specific trans-
port proteins located at the plasma membrane. These trans-
porters belong to two families of integral membrane proteins,
the equilibrative nucleoside transporter family or ENT, with
broad substrate selectivity, and the concentrative nucleoside
transporter family or CNT1 (1–4). The CNT transporters are
Na-dependent, and they differ in substrate selectivity. Among
them, three CNT isoforms have been cloned so far; they are
CNT1, which is pyrimidine-preferring, CNT2, which is purine-
preferring (2–4), and CNT3, which shows broad selectivity,
accepting both pyrimidine and purine nucleosides (5). Besides
the important function of nucleosides as precursors of nucleic
acid and energy-rich molecules, a variety of nucleoside-derived
drugs used in cancer and anti-viral therapies are taken up by
the cells through the nucleoside transporters (2, 3, 6, 7).
Although the electrogenic property of CNT transporters has
been used to study their substrate selectivity at a fixed mem-
brane potential (5–12), the electrophysiological characteristics
of the transport mechanism are not known. Therefore, the
detailed electrophysiological analysis of hCNT1-mediated sub-
strate translocation and inhibitor interaction will be helpful in
the understanding of the minimal structural requirements of
substrates and inhibitors, thus contributing to improve thera-
peutics using hCNT1 as a pharmacological target.
We previously reported that the human Na/nucleoside
transporter pyrimidine-preferring 1 (hCNT1) is electrogenic (6,
7). In the present work we have used electrophysiological meth-
ods to characterize hCNT1 and show the presteady-state cur-
rents, directly determine the Na-nucleoside stoichiometry,
and study the kinetic properties of natural nucleosides and
relevant nucleoside-derived drugs. A major finding of this con-
tribution is also the unequivocal demonstration that adenosine
is not a hCNT1 substrate but can efficiently block the uptake of
pyrimidine nucleosides. Although the impact of this inhibition
in physiology and pharmacology still has to be elucidated, this
finding anticipates new physiological roles for adenosine be-
sides its well known actions as purinergic agonist.
EXPERIMENTAL PROCEDURES
Expression of hCNT1 in Xenopus laevis Oocytes and Uptake Assays—
Stage VI oocytes from X. laevis (Blades Biological, Cowden, UK) were
obtained as previously described (13). They were microinjected with
30–50 ng of mRNA coding for the human Na/nucleoside cotransporter
1, hCNT1 (6), and were maintained at 18 °C in Barth’s medium (88 mM
NaCl, 1 mM KCl, 0.33 mM Ca(NO3)2, 0.41 mM CaCl2, 0.82 mM MgSO4,
2.4 mM NaHCO3 and 10 mM HEPES-Tris, pH 7.4) containing gentamy-
cin (50 mg/liter) and chloramphenicol (1 mg/ml). Experiments were
performed at 22  1 °C 2–7 days after the injection.
Nucleoside uptake was measured by a radiotracer method (14).
Briefly, groups of 6–10 oocytes were incubated for 1 h in 400 l of Na
buffer solution (100 mM NaCl, 2 mM KCl, 1 mM MgCl2, 1 mM CaCl2, and
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10 mM HEPES-Tris, pH 7.5) containing [3H]uridine (specific activity,
36.0 Ci/mmol; PerkinElmer Life Sciences) or [3H]adenosine (specific
activity 23.0 Ci/mmol; Sigma) at the indicated concentrations. Inhibi-
tion of uridine uptake by adenosine was measured by adding the non-
radiolabeled adenosine (2 mM) to the uptake solution containing the
radiolabeled uridine (50 M). After the incubation period had elapsed,
the 3H content of each oocyte was determined by liquid scintillation
counting. Uptakes are expressed as pmol/oocyte h.
Electrophysiology—The electrophysiology experiments were per-
formed using the two-microelectrode voltage clamp method (13, 15, 16).
The oocyte membrane potential was normally held at a holding poten-
tial (Vh) of 50 mV, and continuous current data were recorded using
Axoscope V1.1.1.14 (Axon Instruments, Foster City, CA). To obtain
current/voltage relationship, 11 pulses of potential (test potential) be-
tween 50 and 150 mV (20-mV decrement) were applied for 100 ms
using pClamp 6 software (Axon Instruments, Foster City, CA). The
jump from the holding potential to the test potential generates the “on”
current, and the return from the test potential to the holding potential,
before the next jump, generates the “off ” current.
Steady-state Kinetics—The apparent affinity constant (K0.5
S) and the
maximal current (Imax
S) for saturating nucleoside concentrations were
obtained by fitting the steady-state currents (I) at each membrane
potential to the equation,
l  ImaxS[S]n/(K0.5S)n  [S]n (Eq. 1)
where [S] is the nucleoside concentration (seven concentrations, from 2
M to 1 or 5 mM, depending on the nucleoside), and n is the Hill
coefficient, which for nucleoside kinetic analysis is 1. The fit was per-
formed using the non-linear fitting method in SigmaPlot 8 (SPSS,
Chicago, IL). Uridine, cytidine, thymidine, adenosine, and 5-DFUR
were purchased from Sigma, and gemcitabine was from University
Hospital (University of Navarra, Pamplona, Spain).
For Na activation experiments saturating concentrations of uridine
(0.25 or 0.5 mM) were applied as NaCl concentration was varied be-
tween 0 and 100 mM (0.25, 0.5, 1, 2, 4, 5, 20, and 100 mM), substituting
choline for Na. Uridine-dependent currents at each voltage were fit to
Equation 1, where in this case I is the uridine-induced steady-state
current, Imax
S is maximal uridine current at saturating Na concentra-
tions, [S] is the Na concentration, and K0.5
S is the sodium concentra-
tion at half-maximal current.
The apparent inhibition constant, Ki, for adenosine was determined
at 50-mV membrane potential by measuring uridine or thymidine
(0.25 or 0.50 mM)-induced currents in the presence of different adeno-
sine concentrations (25, 50, 100, 500, 1000, 2500 M) by continuous
current recording. Because uridine/thymidine steady-state currents
slowly decreased with time (Figs. 1B and 6A), the perfusion of uridine/
thymidine in the presence of each adenosine concentration was per-
formed following the Na buffer wash out after the substrate-induced
current had been recorded. The concentration of inhibitor required to
block nucleoside current by 50% (IC50) was first obtained and used to
calculate the Ki using the Cheng-Prusoff equation,
Ki  IC50/(1  [S]/K0.5S) (Eq. 2)
where K0.5
S is the affinity constant for uridine or thymidine, and [S] the
uridine or thymidine concentration.
Presteady-state Currents—The presteady-state transient currents
observed after voltage steps are attributed to changes in the conforma-
tion of the transporter (15–17). These capacitive currents were sepa-
rated from the membrane capacitance and the steady state conduc-
tances using the fitted method (16). The transporter-mediated charge at
each membrane potential was then calculated by integrating the trans-
porter-transient currents with time. In most cases, the “off ” transient
was analyzed. The charge-voltage (Q/V) relations obtained were fit to
the Boltzmann equation,
Q  QhypQmax1 expzVt V0.5	F/RT	
 (Eq. 3)
where Qmax  Qdep  Qhyp, Qdep and Qhyp are the charge moved at
depolarizing and hyperpolarizing limits respectively, z is the apparent
valence of the transporter, Vt is the test potential, V0.5 is the voltage at
FIG. 1. Interaction of adenosine with hCNT1. A, human CNT1
mRNA was injected into oocytes, and 3 days later uptake of 50 M
[3H]uridine (U) in the absence and in the presence of 2 mM adenosine
(A) was measured. Also, uptake of 50 and 250 M [3H]adenosine was
assayed. Uptake of uridine but not of adenosine was found, although
adenosine inhibited uridine uptake by 90%. Data represent the mean
of 8–10 measurements, and the error bars indicate the S.E. NI, non-
injected oocytes. B, a hCNT1-expressing oocyte was held at50 mV and
perfused with Na buffer in the absence of substrate (open box), and
current was continuously recorded (base-line current). The addition of
0.5 mM uridine (arrow and gray box) induced an inward current of 90
nA. The oocyte was then washed out with Na-free buffer (black box),
which blocked the uridine inward current and the base-line current and
with Na buffer until the current returned to base line. The addition of
1 mM adenosine does not induce any inward current, indicating that is
not transported. C, the membrane potential of a hCNT1-expressing
oocyte was clamped at 50 mV, and concentration-dependent inhibi-
tion by adenosine of the uridine-induced current was recorded. The plot
represents the uridine (0.25 mM)-induced current inhibited against the
adenosine concentration (25, 50, 500, 1000, and 2500 M). An IC50 of
73  13 M was obtained and used to calculate Ki (9.4  1.7 M)
according to Equation 2 under “Experimental Procedures.” The dashed
curve is the predicted by Equation 2 using the indicated IC50. For the
three panels similar results were obtained with oocytes from three
different frog donors.
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which the charge was equally distributed between depolarizing and
hyperpolarizing limits, F is Faraday’s constant, R is the gas constant,
and T is the absolute temperature.
Charge/voltage relationship in the presence of adenosine (1, 2, 5, 10,
20, 100, and 1000 M) was obtained for each concentration, and Qmax
was calculated as the difference between Qmax in the absence and
presence of adenosine. Qmax was plotted against adenosine concentra-
tion, and the data were fit to Equation 1 to obtain the binding constant
for adenosine, KD, where I corresponds to Qmax at each adenosine
concentration, [S] is the adenosine concentration, K0.5
S is the binding
constant, and n  1.
Stoichiometry—To determine Na-to-nucleoside-coupling stoichi-
ometry we directly compared unidirectional ligand uptakes (22Na or
[3H]uridine) into voltage-clamped oocytes to the cotransporter (sub-
strate-induced) currents over the same time course in individual cells
(18–20). The nonspecific uptakes of [3H]uridine and 22Na in non-in-
jected oocytes were 1% of the hCNT1-specific uptakes.
Charge-to-nucleoside Stoichiometry—The oocyte was voltage-
clamped at 50 mV and superfused with 100 mM Na medium. When
the base line was stable, 0.5 mM [3H]uridine or [3H]thymidine (specific
activity, 87.0 Ci/mmol; Amersham Biosciences) was added to the Na
solution at a final concentration of 1.4 nCi/l. After 8–10 min the
nucleoside was removed from the bathing solution, and the oocyte was
superfused with Na buffer until the current returned to the base line.
FIG. 2. Membrane current records and steady-state currents of hCNT1 before and after the addition of nucleosides. A, a
hCNT1-expressing oocyte was held at 50 mV and stepped to 11 test values between 50 and 150 mV (20-mV decrement). In Na buffer and
the absence of uridine the oocyte showed presteady-state currents in response to step changes in the membrane voltage and steady-state currents
due to the Na leak through the transporter. B, the addition of 10 mM uridine blocked the presteady-state currents and caused an increase of the
steady-state inward currents. C, steady-state current/voltage relationship induced by 10 mM uridine. The values were obtained as the difference
between the currents obtained in the presence and the absence (Na leak) of uridine. D, a different oocyte from A in which presteady-state currents
were also observed. E, these currents disappeared, and steady-state currents diminished when 1 mM adenosine was added. F, steady-state
current/voltage relationship induced by 1 mM adenosine. Values are obtained as the difference between the currents in the presence and absence
(Na leak) of adenosine. Adenosine decreased the Na leak currents, so the difference between those currents is represented as a positive outward
current.
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The oocyte was recovered from the chamber, rinsed three times in
ice-cold choline buffer, and solubilized with 10% SDS for liquid scintil-
lation counting. Uptake was expressed as pmol/oocyte. [3H]Uridine or
[3H]thymidine uptake in non-injected oocytes was used to correct for
endogenous uridine uptake. Nucleoside-induced current was obtained
as the difference in current between base line and after the addition of
nucleoside and was integrated to obtain total nucleoside-dependent
charge (Qnucleoside). This charge was converted to its molar equivalent
using Faraday’s constant.
Charge-to-Na Stoichiometry—Uptake of 22Na was optimized for
specific activity and transport rate by using a saturating concentration
of uridine (0.5 mM) and a 22Na concentration of 1 mM, close to the
K0.5
Na. The oocyte was clamped at 90 mV and superfused with 1 mM
Na medium. A stable base-line current was recorded, and then the
bath solution was changed to 0.5 mM uridine with 1 mM 22Na
(PerkinElmer Life Sciences) medium at a final concentration of 1.4
nCi/l. After 6–10 min the solution was changed back to the Na
medium until the current returned to base line. The oocyte was washed
and solubilized as described above. The charge associated with the 22Na
uptake induced by uridine was the difference between base-line and
uridine current, whereas 22Na was present. Net charge transported into
the oocyte was obtained by integrating the inward current produced by
the nucleoside uptake in the oocyte. Charge was converted to its molar
FIG. 3. Charge/voltage relationship for adenosine and kinetic
analysis of Qmax. A, the charge (Q) moved in the presence of 0, 2, 10
M adenosine is plotted for each voltage. Charge was obtained by
integration of the transporter presteady-state currents of an oocyte
clamped at 50 mV. The addition of adenosine inhibited Qmax. The
curves are the fit to Equation 3 under “Experimental Procedures.” nC,
nanocoulombs. B, Qmax at each adenosine concentration was calcu-
lated as the difference between Qmax in the absence and presence of
adenosine 1, 2, 5, 10, 20, 100, and 1000 M. Qmax was plotted against
adenosine concentration, and the data were fit to Equation 1 to obtain
the binding constant for adenosine, KD (5.6  0.9 M). Similar results
were obtained with oocytes from four different frog donors.
FIG. 4. Voltage dependence of K0.5 and Imax for uridine, gem-
citabine, and 5-DFUR. For each nucleoside, K0.5 and Imax were ob-
tained at every membrane potential by fitting the steady-state currents
obtained at seven different concentrations (2–5000 M) to Equation 1.
A, K0.5/V curves. For the three nucleosides K0.5 was voltage-indepen-
dent and lower for gemcitabine followed by uridine and 5-DFUR. The
error bars correspond to the error of the mean from at least three
determinations. B and C, Imax/V curves obtained in two different oo-
cytes. Uridine curve correspond to the inward current at saturating
uridine concentrations (0.5 mM), which is equivalent to the Imax. B,
maximal current for gemcitabine is voltage-independent and smaller
than that for uridine. C, Imax for 5-DFUR is voltage-dependent and
higher than that for uridine at all membrane potential. Similar results
were obtained with oocytes from at least three different batches.
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equivalent by using Faraday’s constant. 22Na uptake in non-injected
oocytes was used to correct for endogenous 22Na uptake.
RESULTS
Interaction of Adenosine with hCNT1—Adenosine is a purine
nucleoside that had been described as a substrate of the pyrim-
idine-preferring nucleoside transport system later identified as
CNT1. Nevertheless, discrepancy on the published data and our
preliminary results prompted us to investigate whether adeno-
sine was transported by hCNT1. Fig. 1A shows uptake of 50 M
[3H]uridine by oocytes expressing hCNT1 (187  16 pmol/
oocyteh), but no uptake of 50 or 250 M [3H]adenosine was found.
However, 2 mM adenosine was able to inhibit uptake of 50 M
uridine by 90%, indicating that this nucleoside is not transported
by hCNT1, but it can bind to the transporter. We further dem-
onstrated that adenosine is not a hCNT1 substrate by electro-
physiological methods. A hCNT1-expressing oocyte was clamped
at 50 mV and continuously perfused with Na buffer inducing
a base-line current that corresponds to the Na-leak current in
the absence of substrate. (Fig. 1B). The addition of 0.5 mM uridine
evoked an inward current of 90 nA. This current and the
base-line current disappeared when the oocyte was washed out
with Na-free buffer. The addition of Na buffer returned the
current to the base line. Adenosine at 1 mM concentration, how-
ever, did not evoke any inward current, indicating that is not
transported. We then performed experiments to obtain the ap-
parent inhibition constant, Ki, for adenosine. Fig. 1C shows the
uridine (0.25 mM)-induced current inhibited by different adeno-
sine concentrations as a function of those concentrations in an
oocyte clamped at 50 mV. For this oocyte IC50 was 73  13 M,
and Ki
A, obtained as described under “Experimental Procedures,”
was 9.4 1.7 M. The mean Ki
A of three different determinations
was 6.4  1.1 M.
Another way to determine adenosine affinity constant for
hCNT1 is from the inhibition of the presteady-state currents.
These currents reflect voltage-dependent processes due to
charge movements caused by Na binding/dissociation and
conformational changes involved in the reorientation of the
ligand binding sites of the cotransporter in the membrane. Fig.
2A shows the current traces recorded after step changes in the
membrane voltage in an oocyte held at 50 mV and perfused
with Na buffer in the absence of substrate. The steady-state
currents at 100 ms correspond to the Na leak currents as it
has been observed in many other cation-coupled transporters.
Presteady-state currents can also be observed, especially at
depolarizing membrane potentials. The addition of 10 mM uri-
dine increased the steady-state inward currents and inhibited
the presteady-state currents (Fig. 2B). Fig. 2C represents the
steady-state currents for uridine as a function of voltage. These
TABLE I
Structures and apparent affinity constant for natural substrates and drugs
K0.5 values for natural nucleosides and drugs were calculated at 50-mV membrane potentials by fitting the currents generated by the substrate
at 7 concentrations (2 M–5 mM) to Equation 1 under “Experimental Procedures.” Currents induced by saturating nucleoside concentrations (Imax)
are expressed as the percentage of the current generated by saturating uridine concentrations (0.5 mM). Values are the mean  S.D. of the different
determinations indicated between parentheses.
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currents were obtained as the difference between the currents
registered in the presence and absence of the nucleoside and
increased as the membrane potential was more negative. Fig.
2, D and E, also show, in a different oocyte, the current traces
recorded in the absence (Fig. 2D) and presence of 1 mM aden-
osine (Fig. 2E). As uridine, adenosine inhibited the presteady-
state currents; however, unlike uridine, adenosine did not in-
duce inward currents (see also Fig. 1B) but inhibited the Na-
leak current. This is shown as positive currents obtained as the
difference between the steady-state currents in the presence
and absence of adenosine, which increased at hyperpolarizing
membrane potentials (Fig. 2F). Notice that in Fig. 1B adeno-
sine does not inhibit the Na-leak current due to a lower
expression level of the transporter in that oocyte compared
with the oocyte in Fig. 2F.
Charge movement as a function of membrane potential was
obtained by the integration of the presteady-state current
records in the absence and presence of adenosine 1, 2, 5, 10,
100, and 1000 M. The Qmax in the absence of adenosine was
24 nanocoulombs and decreased with adenosine concentra-
tion to 16, 11, and 5 nanocoulombs in the presence of 2, 10,
and 20 M uridine, respectively (Fig. 3A). V0.5, however, did not
change with increasing concentrations of adenosine: 90  5
mV in the absence of nucleoside and 93  5, 95  5, and
114  5 mV in the presence of 2, 10, and 20 M adenosine
respectively. Fitting the Qmax data to adenosine concentration
(Fig. 3B) indicated a binding constant, KD
A, of 5.6  0.9 M
(mean of four determinations, 6.5  1 M), a value close to the
Ki
A previously obtained. All these results indicated that aden-
osine is not a substrate of hCNT1 but is a high affinity blocker
able to inhibit uridine-induced inward currents, the Na-leak
currents, and the presteady-state currents observed in hCNT1.
Kinetic Parameters for Nucleosides and Na as a Function of
Membrane Potential—We had previously demonstrated that
the drugs gemcitabine and 5-DFUR are substrates of hCNT1.
In the present work we studied the influence of the membrane
potential on the kinetic parameters for the two nucleoside
derivatives. Fig. 4A shows the K0.5
S/V relationship for the two
drugs and uridine. K0.5
S is voltage-independent at hyperpolar-
izing membrane potentials for the three nucleosides, for gem-
citabine, around half that for uridine, and for 5-DFUR, one
order of magnitude higher. At 50 mV K0.5
S values were 11 
4, 27  5, and 268  84 M for gemcitabine, uridine, and
5-DFUR, respectively (Fig. 4A). Imax was voltage-dependent
for uridine (Fig. 4, B and C) and thymidine (data not shown)
but was voltage-independent for gemcitabine (Fig. 4B) and
cytidine (data not shown). Maximal current for gemcitabine
was 49 and 25% that for uridine at 50 and 150 mV, respec-
tively (Fig. 4B), and Imax for 5-DFUR was 170% that for
uridine at all membrane potentials (Fig. 4C).
Table I summarizes the K0.5 values and maximal currents in
percentage of uridine current at saturating concentrations for
the three natural substrates of hCNT1 and the two nucleoside-
derived drugs at 50 mV of membrane potential. The three
natural nucleosides uridine, cytidine, and thymidine show the
same affinity. However, cytidine induces half of the uridine and
thymidine maximal currents. Gemcitabine, a cytidine-derived
drug, shows a decrease in both K0.5 (2-fold) and Imax (2.5-fold)
compared with uridine. The other nucleoside, 5-DFUR, is a
uridine-derived capecitabine metabolite that shows a higher
affinity constant (one order of magnitude) and maximal current
(1.5-fold) than uridine.
Electrophysiological experiments performed to determine
whether H, K, or Cl are involved in the nucleoside trans-
port and contribute to generate the current revealed that none
of them altered the nucleoside-induced current (data not
shown). Therefore, Na is the only ion coupled to nucleoside
transport. The kinetic parameters of Na as a function of
voltage were also obtained. K0.5
Na was voltage-independent at
hyperpolarized membrane potentials (Fig. 5A), 1.3  0.4 and
0.46  0.28 mM at 50 and 150 mV, respectively. Imax
Na was
voltage-dependent (Fig. 5B),55 5 and113 14 nA at50
and 150 mV, respectively. The apparent affinity constant for
Na obtained as the mean from four different determination
was 1.2  0.2 mM at 50 mV membrane potential.
hCNT1 Stoichiometry—To determine charge/nucleoside
stoichiometry we measured nucleoside-induced current and
[3H]uridine or 22Na uptake in the same hCNT1-expressing
oocyte over the equal time course. Fig. 6A shows an example of
an oocyte clamped at50 mV and superfused with 100 mM Na
buffer, which produced the base-line current due to the Na
leak. The addition of 0.5 mM [3H]uridine induced an inward
current of 175 nA. When the nucleoside was removed from
the bath the current returned to the base line. The current was
integrated with time to determine the nucleoside-dependent
net charge influx (Qnucleoside) that was 8.4  105 coulombs of
positive charge. This charge was converted to its molar equiv-
alent, 0.87 nmol, and compared with the nucleoside [3H]uridine
uptake, 0.48 nmol, resulting in a charge-to-nucleoside ratio of
1.81:1 for this oocyte. The same process was repeated with 21
FIG. 5. K0.5 and Imax for Na
 as a function of voltage. The 0.25
mM uridine-induced steady-state currents were measured as a function
of external Na concentration (0, 0.25, 0.5, 1, 2, 4, 5, 20, and 100 mM).
K0.5
Na and Imax
Na were obtained by fitting the currents at each mem-
brane potential to Equation 1 under “Experimental Procedures.”
K0.5
Na was voltage-independent at hyperpolarizing membrane poten-
tials, whereas Imax
Na was voltage-dependent. The errors are errors of
the fit. Similar results were obtained with oocytes from three
different batches.
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oocytes and [3H]uridine or [3H]thymidine concentrations of 0.5
or 0.25 mM. All the data were fitted to a single regression line.
For all oocytes tested, the value of Qnucleoside/nucleoside uptake
was 1.85  0.18 (Fig. 6B), indicating that two net inward
positive charges were transported for every nucleoside
cotransported.
Similar to the former experiments, the relationship between
charge influx and 22Na uptake was measured in 4 oocytes
clamped at 90 mV. The oocytes were superfused with 1 mM
Na solution, and after stable base line, 0.5 mM uridine with 1
mM 22Na was added. The uridine-dependent inward current
was recorded, and 22Na uptake was measured in the same
oocyte. Net charge transported (QNa

) was plotted against the
radiolabeled 22Na uptake, and data were fitted to a regression
line with a slope of 1.07  0.14 (Fig. 6C), indicating that 1 net
inward positive charge was transported for every Na ion
cotransported.
DISCUSSION
The two-electrode voltage clamp technique allows investiga-
tion of the mechanism of membrane transporters and isolates
partial reactions of the transport cycle to determine the mode of
action of substrates and inhibitors. We previously reported that
hCNT1 is electrogenic and transports gemcitabine and 5-
DFUR, an intermediate metabolite of capecitabine and imme-
diate precursor of the active drug 5-fluorouracil (6, 7). Never-
theless a complete electrophysiological characterization of the
basic properties of hCNT1-mediated translocation has not been
performed yet, and more surprisingly, the exact role of adeno-
sine in hCNT1 function has not been addressed either.
Interaction of Adenosine with hCNT1—Adenosine had been
described as a poor substrate of the pyrimidine-preferring
CNT1 transport system. In oocytes expressing rCNT1 and
measuring [3H]adenosine fluxes it was found that adenosine
was transported with a K0.5 of 26 M, close to the K0.5 for
uridine; however, Vmax was 200-fold lower than that for uridine
(21). In COS-1 cells transfected with rCNT1 other authors
obtained a K0.5 for adenosine of 15 M and a Vmax 65-fold lower
than that for uridine (22). Also in oocytes expressing both
human and rat CNT1 it was reported that adenosine is trans-
ported, but the work showed a very small uptake of 10 M
adenosine (0.5 pmol/oocyte/10 min) and a Ki for adenosine of
50  11 M (23). The present results using radiotracer uptake
method and electrophysiological techniques demonstrate that
adenosine is not a substrate of hCNT1 but a good inhibitor with
an apparent affinity 6-fold higher than for uridine (Ki
A 
6.4  1 versus K0.5
U  37  7). Similarly, in oocytes expressing
rat CNT1 it was shown that adenosine did not induce any
inward current but abolished uridine-induced current (9).
Presteady-state currents have been found in several cotrans-
porters families, indicating that the origin of these transient
currents may be similar between them (17, 24–26). Oocytes
expressing hCNT1 also exhibit presteady-state currents after
FIG. 6. Charge-to-nucleoside and charge-to-Na stoichiometry
for hCNT1. A, a representative experiment showing [3H]uridine-in-
duced inward current in an hCNT1-expressing oocyte. Membrane po-
tential was held at 50 mV, and oocyte perfused with Na buffer and
a stable base-line current were recorded. The addition of 0.25 mM
uridine increased the inward current to 175 nA. After 8 min uridine
was removed from the bath by perfusing uridine-free Na buffer, and
the current returned to base line. The transported charge, Q, was
calculated as the integral of the nucleoside-dependent current over 8
min and was 8.4  105 C. The [3H]uridine uptake in this oocyte was
0.45 nmol after subtraction of [3H]uridine uptake over the same period
in non-injected oocytes. B, charge-to-nucleoside stoichiometry of
hCNT1. Uptake of 0.25 mM [3H]uridine or [3H]thymidine in the pres-
ence of 100 mM Na was measured for 5–10 min as indicated in A. The
membrane potential was held at 50 mV. The nucleoside dependent
charge (Qnucleoside) was plotted against the uptake of the nucleoside.
Each point corresponds to one oocyte after subtraction of the non-
injected oocyte uptake. The data were fit to a linear regression with a
slope of 1.85  0.18 charges/nucleoside. C, charge-to-Na stoichiometry
of hCNT1. The uridine-dependent charge and 22Na uptake were simul-
taneously determined at 90 mV membrane potential in different
hCNT1-expressing oocytes. The uridine concentration was 0.5 mM, and
the Na concentration 1 mM. The data were fit to a linear regression
with a slope of 1.07  0.14 charges/Na.
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step changes in membrane voltage in the presence of Na and
the absence of nucleoside with comparable properties. These
currents reveal voltage-dependent processes due to charge
transfer caused by binding and dissociation of Na and the
conformational changes involved in the reorientation of the
ligand binding sites of the cotransporter in the membrane
(15–17). They decrease upon the addition of the substrate uri-
dine or the inhibitor adenosine, as it occurs in others cotrans-
porters (15, 20, 26, 27). This decrease on the presteady-state
currents, which depends on the substrate/inhibitor concentra-
tion, indicates a reduction on charge movement (and, therefore,
the number of functional transporters or Qmax) with a potency
comparable with their apparent K0.5/Ki (14, 16, 27, 28). Accord-
ingly, the apparent inhibition constant for adenosine obtained
by directly measuring the inhibition of uridine/thymidine-in-
duced inward currents and measuring inhibition of the charge
movement of the transporter were similar. Another character-
istic of high affinity inhibitors, which is fulfilled by adenosine,
is that they reduce the number of functional transporters as
their concentration increases, without affecting V0.5 (17, 28).
Kinetic Parameters for Nucleosides and Na as a Function of
Membrane Potential—Using flux measurements in oocytes ex-
pressing hCNT1 K0.5 values for 45 M for uridine and 24 M for
gemcitabine and a Vmax for gemcitabine of 45% that for uridine
(8) were reported. These results are in accordance to those
obtained in the present work. Cytidine and its derivative gem-
citabine induce lower Imax than uridine, but cytidine shows the
same K0.5 than uridine, whereas gemcitabine has higher affin-
ity. On the other hand, 5-DFUR, a uridine derivative, shows
higher Imax and K0.5 than uridine. Likewise, studies performed
using SGLT1 demonstrated that phenylglucosides induce dif-
ferent maximal currents and show different affinities than the
natural substrates. The difference in the maximal currents of
those compounds is explained by a variation in the transloca-
tion rate of the sugar-Na-loaded transporter due to their
structure (14, 29). In rCNT1 it has been found that in the
azacytidine molecule the change of the nitrogen from the 5 to
6-position alters the conformation of the nucleoside and dra-
matically decreases its transport rate (9). Similarly, the differ-
ences between the kinetic parameters of the nucleosides in the
present work can be related to their structure. The lack of
transportability of adenosine by hCNT1 and data obtained
when analyzing its rat ortholog, showing extremely low Vmax
values, support the view that adenosine is not a substrate for
CNT1 in humans and may not be a physiological substrate in
rodents. Selectivity for pyrimidines appears to be determined
by a reduced number of amino acid residues in transmembrane
domains 7 and 8. Ser-319, Gln-320, Ser-353, and Leu-354,
when replaced by the equivalent amino acids of the purine
preferring nucleoside transporter CNT2, result in a switch of
selectivity from pyrimidines into purines (30). Although the
contribution of other residues in nucleoside selectivity cannot
be ruled out, the analysis of the primary structure of both
orthologs, human and rat CNT1, reveal that sequences are
identical particularly in these two transmembrane domains. A
high sequence identity would argue against significant differ-
ences in substrate selectivity among orthologs. Cytidine and
gemcitabine, which show lower Imax, present an NH2 group in
the 4 position of the pyrimidine ring, whereas the other three
nucleosides have an O in that position. Furthermore, gemcit-
abine presents two F residues in the 2 position that may
contribute to the increase in affinity. In the case of 5-DFUR,
the lack of an OH group in the fifth carbon of the ribose ring
and the presence of an F residue in the 5 position of the
pyrimidine ring could explain the changes in its kinetic
parameters.
In rabbit SGLT1 it has been demonstrated that the rate-
limiting step for sugar transport is the empty carrier translo-
cation from the internal to the external face of the membrane
and that the only steps in the transport cycle considered voltage-
dependent are the empty carrier translocation and the Na
binding/dissociation. As the membrane potential is made more
negative, the empty carrier moves faster to the extracellular
face of the membrane, more current is recorded, and the inter-
nal dissociation of Na becomes the rate-limiting step. This
mechanism explains the voltage dependence of the sugar-in-
duced current in SGLT1 (15, 31). For the case of the transport
of helicin, a glucoside derivative whose Imax is voltage-indepen-
dent, it was found that the constant rate of the fully loaded
sugar-Na-carrier complex from the outward to the inward
facing conformation decreases and becomes the rate-limiting
step of the transport cycle (14). Considering the similarity
between the electrogenic properties of SGLT1 and hCNT1, we
propose that the voltage independence of Imax for gemcitabine
and cytidine here found could also be explained as a decrease of
the constant rate of the fully loaded nucleoside-Na-carrier
complex due to the structure differences between these two
nucleosides and uridine, thymidine, and 5-DFUR.
hCNT1 Stoichiometry—Stoichiometry for hCNT1 has been
reported to be 1 nucleoside:1 Na based on the Hill coefficient
analysis (1). The Hill coefficient is often used as an indirect
method to estimate the number of ligand molecules that are
required to bind to a transporter to generate transport. How-
ever, for a transporter with more than one ligand binding site,
the Hill equation does not reflect a physically possible reaction
scheme. Only when the affinity of binding for the first ligand
molecule is much lower than for the subsequent ligand mole-
cules the Hill coefficient is an accurate estimate (32). In the
present work we have directly determined the relationship
between the currents and the nucleoside and Na uptake by
hCNT1. The results indicate that 2 inward charges are intro-
duced for each nucleoside that is transported and that 1 inward
positive charge is transported for each Na ion that is cotrans-
ported with the nucleoside. Therefore, the Na/nucleoside ratio
suggests a stoichiometry of 2:1 and not of 1:1.
Finally, the unequivocal evidence that adenosine is a high
affinity blocker of CNT1 raises the question of whether this
purine nucleoside may exert additional physiological roles be-
sides its known interaction with purinergic receptors. In intes-
tinal and renal epithelia CNT1 and CNT2 are located at the
apical absorptive side. CNT2 is indeed the high affinity con-
centrative nucleoside transporter for adenosine, and thus,
CNT2 function may in practice modulate extracellular adeno-
sine concentrations, which in turn may also determine CNT1
translocation activity. Whether this functional cross-talk really
occurs in physiological models and how this may affect drug
bioavailability requires further analysis.
Acknowledgments—We thank A. Redı´n for technical assistance and
Dr. E. M. Wright and Dr. B. A. Hirayama for the facilities to perform the
charge-to-Na stoichiometry studies.
REFERENCES
1. Griffith, D. A., and Jarvis, S. M. (1996) Biochim. Biophys. Acta 1286, 153–181
2. Pastor-Anglada, M., Felipe, A., and Casado, F. J. (1998) Trends. Pharmacol.
Sci. 19, 424–430
3. Baldwin, S. A., Mackey, J. R., Cass, C. E., and Young, J. D. (1999) Mol. Med.
Today 5, 216–224
4. Casado, F. J., Lostao, M. P., Aymerich, I., Larrayoz, I. M., Duflot, S., Ro-
driguez-Mulero, S., and Pastor-Anglada, M. (2002) J. Physiol. Biochem. 58,
207–216
5. Ritzel, M. W., Ng, A. M., Yao, S. Y., Graham, K., Loewen, S. K., Smith, K. M.,
Ritzel, R. G., Mowles, D. A., Carpenter, P., Chen, X. Z., Karpinski, E., Hyde,
R. J., Baldwin, S. A., Cass, C. E., and Young, J. D. (2001) J. Biol. Chem. 276,
2914–2927
6. Lostao, M. P., Mata, J. F., Larrayoz, I. M., Inzillo, S. M., Casado, F. J., and
Pastor-Anglada, M. (2000) FEBS Lett. 481, 137–140
7. Mata, J. F., Garcia-Manteiga, J. M., Lostao, M. P., Fernandez-Veledo, S.,
Electrophysiological Characterization of hCNT19006
 at Universidad de Navarra, on M
arch 12, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
Guillen-Gomez, E., Larrayoz, I. M., Lloberas, J., Casado, F. J., and Pastor-
Anglada, M. (2001) Mol. Pharmacol. 59, 1542–1548
8. Mackey, J. R., Yao, S. Y., Smith, K. M., Karpinski, E., Baldwin, S. A., Cass,
C. E., and Young, J. D. (1999) J. Natl. Cancer Inst. 91, 1876–1881
9. Dresser, M. J, Gerstin, K. M., Gray, A. T., Loo, D. D. F, and Giacomini, K. M.
(2000) Drug Metab. Dispos. 28, 1135–1140
10. Gerstin, K. M., Dresser, M. J., and Giacomini, K. M. (2002) Am. J. Physiol.
Renal Physiol. 283, 344–349
11. Yao, S. Y., Ng, A. M., Loewen, S. K., Cass, C. E., Baldwin, S. A., and Young,
J. D. (2002) Am. J. Physiol. Cell Physiol. 283, 155–168
12. Loewen, S. K., Ng, A. M., Mohabir, N. N., Baldwin, S. A., Cass, C. E., and
Young, J. D. (2003) Yeast 20, 661–675
13. Birnir, B., Loo, D. D., and Wright, E. M. (1991) Pfluegers Arch. 418, 79–85
14. Lostao, M. P., Hirayama, B. A., Loo, D. D., and Wright, E. M. (1994) J. Membr.
Biol. 142, 161–170
15. Parent, L., Supplisson, S., Loo, D. D., and Wright, E. M. (1992) J. Membr. Biol.
125, 49–62
16. Loo, D. D., Hazama, A., Supplisson, S., Turk, E., and Wright, E. M. (1993) Proc.
Natl. Acad. Sci. U. S. A. 90, 5767–5771
17. Hazama, A., Loo, D. D., and Wright, E. M. (1997) J. Membr. Biol. 155, 175–186
18. Mackenzie, B., Loo, D. D., and Wright, E. M. (1998) J Membr. Biol 162,
101–106
19. Dı´ez-Sampedro, A., Eskandari, S., Wright, E. M., and Hirayama, B. A. (2001)
Am. J. Physiol. Renal Physiol. 280, 278–282
20. Loo, D. D., Eskandari, S., Boorer, K. J., Sarkar, H. K., and Wright, E. M. (2000)
J. Biol. Chem. 275, 37414–37422
21. Yao, S. Y., Ng, A. M., Ritzel, M. W., Gati, W. P., Cass, C. E., and Young, J. D.
(1996) Mol. Pharmacol. 50, 1529–1535
22. Fang, X., Parkinson, F. E., Mowles, D. A., Young, J. D., and Cass, C. E. (1996)
Biochem. J. 317, 457–465
23. Ritzel, M. W., Yao, S. Y., Huang, M. Y., Elliott, J. F., Cass, C. E., and Young,
J. D. (1997) Am. J. Physiol. 272, C707–C714
24. Mackenzie, B., Schafer, M. K., Erickson, J. D., Hediger, M. A., Weihe, E., and
Varoqui, H. (2003) J. Biol. Chem. 278, 23720–23730
25. Forlani, G., Bossi, E., Perego, C., Giovannardi, S., and Peres, A. (2001) Bio-
chim. Biophys. Acta 1538, 172–180
26. Klamo, E. M., Drew, M. E., Landfear, S. M., and Kavanaugh, M. P. (1996)
J. Biol. Chem. 271, 14937–14943
27. Wadiche, J. I., Arriza, J. L., Amara, S. G., and Kavanaugh, M. P. (1995) Neuron
14, 1019–1027
28. Hirayama, B. A., Dı´ez-Sampedro, A., and Wright, E. M. (2001) Br. J Pharma-
col. 134, 484–495
29. Dı´ez-Sampedro, A., Lostao, M. P., Wright, E. M., and Hirayama, B. A. (2000)
J. Membr. Biol. 176, 111–117
30. Loewen, S. K., Ng, A. M., Yao, S. Y., Cass, C. E., Baldwin, S. A., and Young,
J. D. (1999) J. Biol. Chem. 274, 24475–24484
31. Parent, L., Supplisson, S., Loo, D. D., and Wright, E. M. (1992) J. Membr. Biol.
125, 63–79
32. Weiss, J. N. (1997) FASEB J. 11, 835–841
Electrophysiological Characterization of hCNT1 9007
 at Universidad de Navarra, on M
arch 12, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
Additions and Corrections
Vol. 279 (2004) 8999–9007
Electrophysiological characterization of the human
Na/nucleoside cotransporter 1 (hCNT1) and role of
adenosine on hCNT1 function.
Ignacio M. Larra´yoz, Francisco Javier Casado, Marc¸al
Pastor-Anglada, and M. Pilar Lostao
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Page 38548: There are two errors in the next to last paragraph
in the left-hand column:
Line 3 should read “ . . . effect on Cx26/Cx32 channels.”
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